VOLOCIXIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Fri Dec 15 16:54:07 UTC 2023` Edited by `admin` on `Fri Dec 15 16:54:07 UTC 2023`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG4
Sequence Origin	MOUSE CHIMERIC
Sequence Type	COMPLETE
Record UNII	496K5Z02NW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VOLOCIXIMAB

Official Name

English

M200

Code

English

M-200

Code

English

volociximab [INN]

Common Name

English

Volociximab [WHO-DD]

Common Name

English

IMMUNOGLOBULIN G4, ANTI-(HUMAN .ALPHA.5.BETA.1 INTEGRIN) (HUMAN-MOUSE CLONEP200-M HEAVY CHAIN), DISULPHIDE WITH HUMAN-MOUSE CLONE P200-M .KAPPA.-CHAIN, DIMER -

Common Name

English

VOLOCIXIMAB [USAN]

Common Name

English

IMMUNOGLOBULIN G4, ANTI-(HUMAN .ALPHA.5.BETA.1 INTEGRIN) (HUMAN-MOUSE CLONEP200-M HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE CLONE P200-M .KAPPA.-CHAIN, DIMER -

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C20401

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

Code System Code Type Description

EVMPD

SUB126746

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

PRIMARY

CAS

558480-40-3

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

PRIMARY

USAN

QQ-34

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

PRIMARY

WIKIPEDIA

VOLOCIXIMAB

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

PRIMARY

INN

8600

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

PRIMARY

ChEMBL

CHEMBL2108061

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

PRIMARY

DRUG BANK

DB06647

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

PRIMARY

FDA UNII

496K5Z02NW

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

PRIMARY

MESH

C516631

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

PRIMARY

NCI_THESAURUS

C48426

Created by admin on Fri Dec 15 16:54:07 UTC 2023 , Edited by admin on Fri Dec 15 16:54:07 UTC 2023

PRIMARY

From	To
1_22	1_95
1_138	1_151
1_207	3_215
1_230	2_230
1_233	2_233
1_265	1_325
1_371	1_429
2_22	2_95
2_138	2_151
2_207	4_215
2_265	2_325
2_371	2_429
3_23	3_89
3_135	3_195
4_23	4_89
4_135	4_195

Related Record Type Details


					QTM0X1O16Y

INTEGRIN ALPHA-5/BETA-1

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					496K5Z02NW

ACTIVE MOIETY

Comments:

Overall good tolerance, with minor constitutional adverse events, was described in a phase I study testing doses up to 15 mg/kg QWK. Although single-agent anti-tumor activity was disappointing, the good safety profile led to a trial combining volociximab with carboplatin/paclitaxel in non-small cell lung cancer.

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:SEQUENCE	CHEMICAL
Molecular Formula	CHEMICAL